Ontology highlight
ABSTRACT:
SUBMITTER: Gibney GT
PROVIDER: S-EPMC3983565 | biostudies-literature | 2013 Jul
REPOSITORIES: biostudies-literature
Gibney Geoffrey T GT Messina Jane L JL Fedorenko Inna V IV Sondak Vernon K VK Smalley Keiran S M KS Smalley Keiran S M KS
Nature reviews. Clinical oncology 20130528 7
The clinical benefits of BRAF inhibition in patients with advanced-stage BRAF-mutant melanoma are now well established. Although the emergence of cutaneous squamous-cell carcinomas (SCCs) and secondary melanomas in patients on BRAF-inhibitor therapy have been well described, reports are emerging of additional secondary premalignant and malignant events, including RAS-mutant leukaemia, the metastatic recurrence of RAS-mutant colorectal cancer and the development of gastric and colonic polyps. In ...[more]